Antaros Medical to talk about using imaging to understand obesity, insulin resistance, and downstream organ effects at the T2D & Obesity summit

Lars Johansson (CSO @ Antaros Medical) will present later this week at the Novel Therapies for Type 2 Diabetes & Obesity Summit. His talk will focus on how imaging can be utilised in clinical trials for drug development to better understand insulin resistance, body composition, and downstream effects in the liver, kidney, heart, and muscle.

Type 2 diabetes (T2D) and obesity are both significant global health problems that are rapidly increasing in prevalence. The underlying pathophysiology driving drug development in obesity, diabetes, and various downstream organ effects is undeniably linked. Therapies originally developed for treating T2D have also been shown to affect weight loss and body composition, as well as in treating the downstream organ effects related to T2D.

The overall complexity and interrelatedness of these mechanisms and processes create a need for biomarkers that can help with furthering our understanding and inform decision making throughout the drug development process. Advanced imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) can be used to investigate insulin resistance, body composition, and end organ effects.

To find out more, join us at the Novel Therapies for T2D & Obesity Summit on Wednesday May 31 @ 14:00 EDT to hear Lars’ presentation on the benefits of using imaging in T2D and obesity drug development. The T2D & Obesity Summit takes place from May 30 – June 1 in Boston, MA. You can also read more about our work in T2D and Obesity in our publications.

Share on Linkedin Share on Twitter